The most compelling evidence has emerged in hepatocellular carcinoma and multiple myeloma, where Resminostat has demonstrated clinically meaningful activity, reinforcing the therapeutic value of multi-HDAC targeting approaches in complex, treatment-resistant cancers. Here, HDAC9 is linked to cancer.